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Abstract: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme -galactosidase A. FD 
causes glycolipids, such as globotriaosylceramide (Gb3), to accumulate in the vascular endothelium of several organs (Fig. 2), including 
the skin, kidneys, nervous system, and heart, thereby triggering inflammation and fibrosis. These processes generally result in organ dys-
function, which is usually the first clinical evidence of FD. Patients with classic FD have various symptoms, eg, acroparesthesias, hypo-
hidrosis, angiokeratomas, corneal opacities, cerebrovascular lesions, cardiac disorders, andrenal dysfunction.However, evolving knowl-
edge about the natural course of disease suggests that it is more appropriate to describe FD as a disease with a wide spectrum of hetero-
geneously progressive clinical phenotypes. Indeed, most female heterozygotes develop symptoms due to yet undetermined mechanisms 
and a high percentage of females develops vital organ involvement including the kidneys, heart and/or brain about a decade later than 
males. Renal failure is a serious complication of this disease. Fabry nephropathy lesions are present and progress in childhood while the 
disease commonly remains silent by routine clinical measures. Early and timely diagnosis of Fabry nephropathy is crucial since late ini-
tiation of enzyme replacement therapy may not halt progressive renal dysfunction. This may be challenging due to difficulties in diagno-
sis of Fabry disease in children and absence of a sensitive non-invasive biomarker of early Fabry nephropathy. Accurate measurement of 
glomerular filtration rate and regular assessment for proteinuria and microalbuminuria are useful, though not sensitive enough to detect 
early lesions in the kidney. The principal clinical manifestations in Fabry disease consist of artery associated complications (such as cere-
bral disease and nephropathy), but the pathophysiology of this specific vasculopathy is unclear. Several studies indicate that the specific 
vascular lesions that are present in Fabry disease occur as a result of vascular dysfunction with major components being endothelial dys-
function, alterations in cerebral perfusion and a pro-thrombotic phenotype. Fabry cardiac involvement has several clinical manifestations 
(Table 10): concentric left ventricular hypertrophy without left ventricular dilation and severe loss of left ventricular systolic function, 
mitral and aortic valvulopathy, disorders of the atrioventricular conduction or repolarization, and compromised diastolic function. The 
neurological manifestations of Fabry disease include both peripheral nervous system and CNS involvement, with globotriaosylceramide 
accumulation found in Schwann cells and dorsal root ganglia together with deposits in CNS neurones. The main involvement of the CNS 
is attributable to cerebrovasculopathy, with an increased incidence of stroke. The abnormal neuronal accumulation of glycosphingolipid 
appears to have little clinical effect on the natural history of Fabry disease, with the possible exception of some reported mild cognitive 
abnormalities. The pathogenesis of Fabry vasculopathy remains poorly understood, but probably relates, in part, to abnormal functional 
control of the vessels, secondary to endothelial dysfunction as a consequence of -galactosidase A deficiency. The diagnosis of Fabry 
disease is made in hemizygous males after the detection of the presence of angiokeratomas (Fig. 19 A, B), irregularities in sweating, 
edema, scant body hair, painful sensations, and of cardiovascular, gastrointestinal, renal, ophthalmologic, phlebologic, and respiratory in-
volvement. A deficiency of alpha-gal A in serum, leukocytes, tears, tissue specimens, or cultured skin fibroblasts further supports the di-
agnosis in male patients. Since heterozygous women show angiokeratomas in only about 30% of cases and may have alpha-gal A levels 
within normal range, genetic analysis is recommended. The resultant storage of undegraded glycolipids leads to the progressive devel-
opment of potentially life-threatening manifestations affecting multiple organ systems in the body. The Mainz Severity Score Index 
(MSSI) (Table 12), a scoring system for patients with Fabry disease has been proven to be representative in patients with 'classic' Fabry 
disease and may be useful for monitoring clinical improvement in patients receiving enzyme replacement therapy. The MSSI of patients 
with AFD was significantly higher than that of patients with other severe debilitating diseases. 
Keywords: ?????????????????????????????????????. 
INTRODUCTION 
 Lysosomal storage diseases (LSDs) comprise a group of at least 
50 distinct genetic diseases, each one resulting from a deficiency of 
a particular lysosomal protein/activity (Fig. 1) or, in a few cases, 
from non-lysosomal activities that are involved in lysosomal bio-
genesis or protein maturation. Fabry disease is the second most 
common of the LSDs, after Gaucher disease [1].  
 Fabry disease (FD) is a rare X-linked lysosomal storage disor-
der caused by a deficiency of the enzyme -galactosidase A [2]. FD 
causes glycolipids, such as globotriaosylceramide (Gb3), to accu-
mulate in the vascular endothelium of several organs (Fig. 2), in-
cluding the skin, kidneys, nervous system, and heart, thereby trig-
gering inflammation and fibrosis [3]. These processes generally 
result in organ dysfunction, which is usually the first clinical evi-
dence of FD. Patients with classic FD have various symptoms, eg,  
 
*Address correspondence to this author at the Dipartimento Biomedico di 
Medicina Interna e Specialistica, Università degli Studi di Palermo (Italy); 
Tel:/Fax: ??????????????????????????????????????; 
E-mail: bruno.tuttolomondo@unipa.it 
acroparesthesias, hypohidrosis, angiokeratomas, corneal opacities, 
cerebrovascular lesions, cardiac disorders, andrenal dysfunction. 
The symptoms are progressively debilitating, reduce the ability of 
patients to attend work or school, and severely affect quality of life 
(Tables 1, 2, 3). 
 Although the primary pathologic process - i.e., accumulation of 
Gb3 - is initiated at early stages in life, the course of the disease, in 
particular progression to vital organ involvement such as end-stage 
renal disease and heart failure, can differ widely between patients, 
even in individuals with the same underlying genotype. A current 
disease model describes the accumulation of Gb3 in different organ 
systems as the primary insult, followed by secondary cellular dys-
function, ischemia and fibrosis eventually leading to severe end-
organ damage and failure. The process of Gb3 accumulation, start-
ing in the unborn child, can be subclinical for many years until 
secondary disease processes lead to organ dysfunction and specific 
pathologies can be detected. It seems to be obvious that the onset of 
clinically evident dysfunction occurs at a comparable late stage of 
the disease. Taking this into account, the occurrence of proteinuria 
and reduction of glomerular filtration rate (GFR) in a Fabry patient  
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Table 1. [From Robert J Hopkin, John Bissler
 
and Gregory 
A Grabowski. Comparative evaluation of -
galactosidase A infusions for treatment of Fabry 
disease. Genetics in Medicine (2003)] 
 
 
after a stable plateau for 2-3 decades may represent already consid-
erable renal damage leading to ultimate organ failure in a compara-
bly short period of time. 
 Clinical manifestations in affected hemizygous males are pri-
marily due to progressive disease/involvement of small vessels, 
including angiokeratoma, autonomic dysfunction, and lifelong de-
bilitating pain. Renal failure and vasculopathy of the heart and brain 
lead to early demise in adulthood. Demonstration of alpha-
galactosidase A deficiency in leukocytes or plasma is the definitive 
method for the diagnosis of affected hemizygous males. Most fe-
male carriers are clinically symptomatic, they may present isolated 
acroparesthesias, cardiac symptoms, or the characteristic benign 
corneal dystrophy. Due to random X-chromosomal inactivation,  
 
Table 2. [ From: Christine M Eng, Dominique P Germain
 
et 
al. Fabry disease: Guidelines for the evaluation and 
management of multi-organ system involvement. 
Genetics in Medicine (2006) ] 
 
enzymatic detection of carriers is often inconclusive. A reliable 
molecular test for detection of heterozygosity is therefore highly 
desirable for accurate genetic counselling. The GLA gene has been 
mapped to chromosome Xq22, and cloned. Several studies have 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Lysosomal storage diseases can result from a deficiency of a single lysosomal enzyme. 
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shown the molecular heterogeneity of the disease. Currently, no 
standard treatment exists for Fabry disease. Symptomatic treatment 
is provided as appropriate. In addition, renal transplantation or di-
alysis is available for patients experiencing end-stage renal failure. 
 Over the past 7 years, the Fabry Outcome Survey (FOS) has 
collected data on the natural history of Fabry disease, and the long-
term efficacy and safety of enzyme-replacement therapy. An article 
by Mehta et al. [4] provides an update on the first analysis of FOS 
data. Baseline data on clinical manifestations and causes of death in 
a cohort of 1453 patients (699 male, 754 female) from 19 countries 
worldwide were analysed. Causes of death of affected relatives 
were analysed separately (Table 4). 
 The most frequently reported signs and symptoms of Fabry 
disease were neurological. Cardiac, ocular, gastrointestinal, derma-
tological, auditory and renal manifestations were also common. The 
principal causes of death among 181 affected relatives of patients in 
FOS (most of whom had died before 2001) were renal failure in 
males (42%) and cerebrovascular disease in females (25%). In con-
trast, of the 42 patients enrolled in FOS whose deaths were reported 
between 2001 and 2007, cardiac disease was the main cause of 
death in both male (34%) and female (57%) patients. These data 
suggest that the importance of renal disease as a cause of death in 
patients with Fabry disease is decreasing while the importance of  
 
 
 
 
 
 
 
 
 
 
Fig. (2). Endothelial cells (electron microscopy): typical inclusions of AFD(in black), in the lysosomes; they appear thick, lamellar. Courtesy Pr. Massi Uni-
versity of Florense, Italy. 
Table 3. [ From: Natalie Jansen Street, Michael S Yi, Laurie A Bailey,R J Hopkin. Comparison of health-related quality of life 
between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease. 
Genetics in Medicine (2006)] 
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Table 4. [From: Atul Mehta and Urs Widmer. Causes of 
death reported in male (n = 66) and female (n = 38) 
relatives of patients in FOS - the Fabry Outcome 
Survey - who are presumed to have had Fabry dis-
ease. Natural history of Fabry disease Chapter 19] 
Reported Cause of Death Males Females 
Cardiac 11 8 
Cardiac/renal 4 0 
Cardiac/cerebrovascular 0 3 
Renal  33 4 
Renal/cerebrovascular 3 0 
Cerebrovascular  5 5 
Cancer  1 8 
Vascular 2 2 
Suicide  2 0 
Lung  0 2 
Gastric  0 1 
Unknown  5 5 
 
cardiac disease is increasing. This pattern probably reflects im-
provements in the management of renal disease in patients with 
Fabry disease. These findings contribute to delineate the clinical 
profile of a multiorgan disease (Table 5). 
ANDERSON-FABRY DISEASE AS A MULTIORGAN DIS-
EASE  
 AFD has long been regarded as an adult disease with most, if 
not all, affected males developing a “classic” phenotype. Later on, 
the sub-classifications “cardiac variant” [5,6] and “renal variant”[7] 
were introduced for patients with predominant or exclusive cardiac 
or renal involvement, respectively. Female heterozygotes were 
erroneously described as “carriers of the defective gene” more or 
less safeguarded against developing of disease manifestations and 
symptoms. However, evolving knowledge about the natural course 
of disease suggests that it is more appropriate to describe FD as a 
disease with a wide spectrum of heterogeneously progressive clini-
cal phenotypes.  
 This spectrum ranges from the “classic” severe phenotype in 
males to a seemingly asymptomatic disease course occasionally 
observed in females, with a variety of clinical presentations [8] 
(Table 6). Indeed, most female heterozygotes develop symptoms 
due to yet undetermined mechanisms [9,10] and a high percentage 
of females develops vital organ involvement including the kidneys, 
heart and/or brain about a decade later than males. 
 A number of Fabry cohort studies and post-marketing registry 
studies have been reported in the literature, describing the natural 
history of FD in males [11,12], females [13,14,15,16]. These stud-
ies have shown that despite residual enzyme activity, FD females 
do develop signs and symptoms of FD, such as left ventricular hy-
pertrophy, proteinuria, stroke and, to a lesser extent, renal failure. 
The prevalence of acroparesthesia, a well known symptom of Fabry 
disease, ranges from 23 to 90% of the patients in the different co-
hort studies. These studies also reported a high prevalence of other 
non-specific complaints such as fatigue, palpitations, chest pain, 
abdominal pain and diarrhoea in FD females. As all of these symp-
toms are non-specific, care should be taken to attribute them di-
rectly to FD, especially as these studies lack control groups. At the 
outpatient clinic, Fabry females sometimes report symptoms or 
complaints of which both patient and the treating physician are 
unsure whether that complaint is part of the clinical spectrum of 
FD. The only way to appreciate whether certain complaints, as-
pecific or not, are part of the spectrum of FD is to study their preva-
lence in comparison with an appropriate control group. Bouwman 
et al. in a recent study [17] explore the prevalence of signs and 
symptoms in FD females in comparison to a control group. In this 
study FD females and age-matched controls were approached to 
complete a questionnaire. This questionnaire was developed by the 
Dutch Fabry patient organization (Fabry Support en Informatie 
Groep Nederland, FSIGN) with input from Fabry expert-physicians 
from the AMC. Authors compared the prevalence of symptoms 
using Pearson's chi-square test. Bonferroni correction was used to 
correct for multiple comparisons. A total of 63 heterozygotes and 
52 controls completed the questionnaire. Many symptoms were also 
common in controls. In addition to acroparesthesia - fatigue, palpi-
tations, dizziness, proteinuria during pregnancy, libido loss and 
joint pain are more prevalent in FD females as compared to a con-
trol group. Although, these symptoms are present in a significant 
proportion of normal controls they deserve further attention by 
treating physicians to better understand their significance, treatment 
and relationship with FD (Table 6). 
 Another study with regard of type of multiorgan involvement 
according symptomatology in patients with AFD disease has been 
conducted by Wilcox et al. on the basis of Fabry Registry [18]. The 
Fabry Registry is a global clinical effort to collect longitudinal data 
on AFD. In the past, most "carrier" females were usually thought to 
be clinically unaffected. A systematic effort has been made to enroll 
all FD females, regardless of symptomology. Of the 1077 enrolled 
females in the Registry, 69.4% had symptoms and signs of FD. The 
median age at symptom onset among females was 13 years, and 
even though 84.1% had a positive family history, the diagnosis was 
not made until a median age of 31 years. Twenty percent experi-
enced major cerebrovascular, cardiac, or renal events, at a median 
age of 46 years. Among adult females with estimated glomerular 
filtration rate (eGFR) data (N=638), 62.5% had an eGFR <90 
ml/min/1.73 m
2
 and 19.0% had eGFR <60 ml/min/1.73 m
2
. Prote-
inuria 300 mg/day was present in 39.0% of females, and 22.2% had 
>1 gram/day. Quality of life (QoL), as measured by the SF-36((R)) 
survey, was impaired at a later age than in males, but both genders 
experience significantly impaired QoL from the third decade of life 
onward. Findings of this study have showed that females with AFD 
have a significant risk for major organ involvement and decreased 
QoL.  
ORGAN INVOLVEMENT 
Fabry Nephropathy 
 Renal failure is a serious complication of this disease. Fabry 
nephropathy lesions are present and progress in childhood while the 
disease commonly remains silent by routine clinical measures. 
Early and timely diagnosis of Fabry nephropathy is crucial since 
late initiation of enzyme replacement therapy may not halt progres-
sive renal dysfunction. This may be challenging due to difficulties 
in diagnosis of Fabry disease in children and absence of a sensitive 
non-invasive biomarker of early Fabry nephropathy. Accurate 
measurement of glomerular filtration rate and regular assessment 
for proteinuria and microalbuminuria are useful, though not sensi-
tive enough to detect early lesions in the kidney. Recent studies 
support the value of renal biopsy in providing relevant histological 
information to kidney function and prognosis, and renal biopsy 
could potentially be used to guide treatment decisions in young 
Fabry patients. This review aims to provide an update of the current 
understanding, challenges, and needs to better approach renal com-
plications of Fabry disease in children. Progressive cellular accu-
mulation of glycolipids starts early in life and, if untreated, eventu-
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Table 5.   
 Frequency Age at symptom onset (years) 
 Proportion of population (%) Number of patients Mean ± SD Number of patients 
 Cerebrovascular 20.0 75 33.5 ± 14.5 52 
 Stroke  8.5 32 39.4 ± 12.1 26 
 TIA(transient ischaemic attack)  8.8 33 32.4 ± 14.5 23 
 Neurological 82.9 311 16.3 ± 15.7 180 
 Pain attacks  69.3 260 13.6 ± 13.6 188 
 Chronic pain  49.9 187 17.2 ± 15.9 128 
 Cardiac 61.1 229 32.9 ± 14.5 141 
 Chest pain  19.5 73 38.4 ± 12.4 59 
 Palpitations  20.3 76 35.7 ± 12.8 51 
 Left ventricular hypertrophy  40.3 151 39.4 ± 11.5 92 
 Renal/urinary 57.3 215 33.9 ± 13.1 143 
 Proteinuria  45.9 172 33.2 ± 12.4 113 
 Haemodialysis  9.6 36 39.6 ± 13.2 32 
 Peritoneal dialysis  2.7 10 42.7 ± 7.1 8 
 Transplantation  8.8 33 37.2 ± 11.6 28 
 Gastrointestinal 56.3 211 23.3 ± 16.2 138 
 Diarrhoea  36.3 136 23.9 ± 16.9 89 
 Abdominal pain  41.1 154 22.4 ± 15.5 117 
 Constipation  13.6 51 23.3 ± 17.5 38 
 Auditory 56.3 211 29.9 ± 14.6 129 
 Tinnitus  31.7 119 28.1 ± 13.7 87 
 Vertigo  29.1 109 29.6 ± 14.4 77 
 Sudden deafness  6.1 23 30.8 ± 14.5 15 
 Ophthalmological 62.1 233 28.4 ± 14.7 151 
 Cornea verticillata  46.1 173 28.4 ± 14.0 120 
 Tortuous vessels  26.4 99 31.9 ± 13.1 67 
 Posterior subcapsular cataract  7.2 27 31.4 ± 16.0 16 
 Dermatological 70.1 263 18.7 ± 14.7 147 
 Angiokeratoma  65.9 247 18.7 ± 13.9 139 
 Telangiectasia  22.1 83 26.1 ± 16.6 46 
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Table 6. Prevalence of Symptoms in FD Females and Controls 
 Fabry Control OR (95% CI) P value 
Cardiopulmonary symptoms     
Palpitations  29/61(48%) 7/53(13%) 5.96(2.32-15.3) 0.001 
Skipped heartbeat 20/60(33%) 6/53(11%) 3.92(1.43-10.7) 0.006 
Chest pain  18/62(29%) 5/51(10%) 3.76(1.29-11.0) 0.01 
Shortness of breath 30/62(48%) 10/53(19%) 4.03(1.72-9.43) 0.01 
Gastrointestinal symptoms     
Regurgitation  23/61(38%) 16/52(31%) 1.36(0.62-2.98) 0.44 
Reflux  18/62(29%) 11/52(21%) 1.52(0.64-3.61) 0.34 
Nausea  27/62(44%) 11/53(21%) 2.95(1.28-6.77) 0.01 
Swallowing difficulties 19/61(31%) 6/53(11%) 3.54(1.29-9.71) 0.001 
Hiccup  25/58(43%) 18/51(35%) 1.39(0.64-3.01) 0.40 
Abdominal pain 37/62(60%) 16/53(30%) 3.42(1.58-7.43) 0.002 
Diarrhea  25/61(41%) 10/53(19%) 2.99(1.27-7.03) 0.01 
Constipation  21/61(34%) 5/53(9%) 5.04(1.74-14,6) 0.002 
Flatulence  34/62(55%) 25/53(47%) 1.36(0.65-2.84) 0.41 
Musculoskeletal symptoms     
Myalgia 35/62(57%) 19/53(36%) 2.32(1.09-4.93) 0.03 
Muscle cramps  25/62(40%) 8/53(15%) 3.80(1.53-9.42) 0.003 
Back ache 38/61(62%) 17/53(32%) 3.50(1.61-7.60) 0.001 
Joint pain 36/62(58%) 13/52(25%) 4.15(1.86-9.29) 0.001 
Pain in hands 36/62(58%) 6/53(11%) 10.85(4.04-20.1) 0.001 
Pain in feet 24/61(39%) 5/53(9%) 6.23(2.17-17.9) 0.001 
Neuropsychological symptoms     
Loss of strenght 28/62(45%) 8/53(15%) 4.63(1.88-11.4) 0.001 
Numbness  8/61(13%) 8/53(15%) 0.85(0.30-2.44) 0.56 
Fatique  55/62(89%) 30/53(57%) 6.02(2.32-15.7) 0.001 
Dizziness  37/62(60%) 10/53(19%) 6.36(2.71-15.0) 0.001 
Headache  36/62(60%) 24/53(45%) 1.67(0.80-3.59) 0.12 
Depressed mood 34/62(55%) 20/51(39%) 1.88(0.89-3.99) 0.19 
Urogenital symptoms     
Urinary incontinence 16/62(26%) 12/53(23%) 1.19(0.50-2.80) 0.69 
Dysuria  3/62(4.8%) 1/53(1.9%) 2.64(0.27-26.2) 0.62 
Premenstrual symptoms 26/40(65%) 20/34(29%) 1.30(0.51-3.34) 0.59 
Menstrual symptoms 24/35(67%) 23/31(74%) 0.76(0.26-2.22) 0.42 
Menarche at 12-15 years 44/62(71%) 36/53(68%9 NA 0.72 
Fertility problems  5/40(13%) 1/39(2.6%) 5.43(0.60-48.8) 0.20 
Anderson-Fabry Disease Current Pharmaceutical Design, 2013, Vol. 19, No. 00    7 
(Table 6) Contd…. 
 
 Fabry Control OR (95% CI) P value 
Loss of libido 27/45(60%) 9/31(23%) 3.67(1.38-9.75) <0.001 
Dermatological symptoms     
Dry skin  42/61(68%) 25/53(47%) 2.48(1.15-5.32) 0.03 
Acne  10/61(16%) 6/53(11%) 1.54(0.52-4.55) 0.44 
Eczema  11/62(18%) 7/53(13%) 1.42(0.51-3.96) 0.50 
Vitiligo  6/62(10%) 5/53(9%) 1.03(0.21-3.58) 0.97 
Urticaria  3/61(4.9%) 2/52(3.8%) 1.29(0.21-8.05) 1.00 
Other symptoms     
Hypohidrosis  17/59(29%) 5/51(10%) 3.72(1.26-11.0) 0.01 
Spontaneous tear in molar 13/60(22%) 10/49(20%) 1.08(0.43-2.73) 0.87 
Allergy  10/62(16%) 9/53(17%) 0.94(0.35-2.52) 0.90 
Snoring  20/62(32%) 31/53(56%) 0.34(0.16-0.73) 0.30 
Gum disease  16/62(26%) 6/53(11%) 2.72(0.98-7.58) 0.05 
 
ally leads to organ failure and premature death. The Fabry neph-
ropathy is characterized by initial proteinuria in the second to third 
decades of life, and development of structural changes including 
glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Pro-
gressive kidney failure develops at a comparable rate as in diabetic 
nephropathy. First signs of kidney damage may arise in childhood, 
prior to first signs of overt renal dysfunction underscoring the key 
importance of early recognition and diagnosis. Globotriaosylcera-
mide (Gb-3) deposition is probably the initiating factor of the dis-
ease pathogenesis and, with enzyme replacement therapy (ERT), 
clearance can be achieved in several cell types. However, some 
late-stage effects are not reversible. As there is growing evidence 
that renal outcomes are more directly related to the degree of fibro-
sis and scarring, preventing the development of these irreversible 
changes by early initiation of ERT may have the greatest impact on 
renal outcomes. Proteinuria should be rigorously monitored and 
aggressively treated with antiproteinuric therapy. 
 Accumulation in the kidney is responsible for progressive de-
cline in renal function in male patients with the classical phenotype, 
resulting in renal failure in their third to fifth decades of life. In a 
study by Valbuena et al. [19] GLA knockout mice ("Fabry mice") 
were generated as an animal model for Fabry disease but, as they do 
not manifest progressive chronic kidney disease (CKD), their rele-
vance as a model for human Fabry nephropathy is uncertain. 
Authors evaluated the histological alterations in the kidneys of 
Fabry mice at different ages, as contrasted to those observed in 
wild-type mice. Furthermore, authors compared the renal histologi-
cal alterations of Fabry mice to the kidney pathology reported in 
patients with Fabry disease at comparable age ranges and across 
different CKD stages, using a scoring system that has been devel-
oped for Fabry nephropathy. Fabry mice are phenotypically differ-
ent from wild-type mice, displaying progressive age-related accu-
mulation of glycosphingolipids in all types of renal cells. There 
were no statistically significant differences between Fabry mice and 
Fabry patients in the prevalence of glycosphingolipid storage per 
renal cell type with the exceptions of mesangial (higher in humans) 
and proximal tubular cells (higher in mice). However, Fabry mice 
lack the nonspecific histological glomerulosclerotic and interstitial 
fibrotic renal lesions that best correlate with progressive CKD in 
Fabry patients, and do not develop large podocyte inclusions. Find-
ings of this study postulate that the elucidation of the mechanisms 
underlying these species differences, may contribute important 
clues to a better understanding of the pathogenesis of Fabry neph-
ropathy. 
 Accumulation of Gb3 occurs mainly in the epithelial cells of 
Henle's loop and distal tubule, inducing early impairment in renal 
concentrating ability; involvement of the proximal tubule induces 
Fanconi syndrome. All types of glomerular cells are involved, espe-
cially podocytes, and glomerular proteinuria may occur at a young 
age. The evolution of renal Fabry disease is characterized by pro-
gressive deterioration of renal function to end-stage renal failure 
(ESRF). Ultrastructural study of kidney biopsies reveals typical 
bodies in the cytoplasm of all types of renal cells, characterized by 
concentric lamellation of clear and dark layers with a periodicity of 
35-50 [20] (Fig. 3). 
 In Anderson-Fabry disease the enzymatic defect, transmitted by 
an X-linked recessive gene, leads to the accumulation of neutral 
glycosphingolipids with terminal alpha-galactosyl residues in the 
plasma and in the lysosomes of endothelial, perithelial, and smooth 
muscle cells of the cardiovascular-renal system and, to a lesser 
extent, in reticuloendothelial, myocardial and connective tissue 
cells. Epithelial cells in the kidney, cornea, and other tissues contain 
the lysosomal depositions, as do the ganglia and perineural cells of 
the autonomic nervous system. The major accumulated substrate is 
globotriaosylceramide [galactosyl-(alpha 1----4)-galactosyl-(beta 1-
---4)-glucosyl-(beta 1----1')-ceramide]; another substrate, galabio-
sylceramide [galactosyl-(alpha 1----4)-galactosyl-(beta 1----1')-
ceramide] is deposited primarily in renal lysosomes. The clinical 
manifestations of Fabry disease are the sequelae of the anatomical 
and physiologic alterations produced by progressive glycosphin-
golipid deposition. Renal manifestations are observed relatively 
early in the course of the disease. Renal biopsy specimens reveal 
evidence of diffuse intracytoplasmic glycosphingolipid accumula-
tion, mainly affecting podocytes and epithelial cells of distal tu-
bules, which are strikingly enlarged and vacuolated. On electron 
microscopy the deposits appear as typical osmiophilic inclusion 
bodies in the cytoplasm of all kinds of renal cells, and show a char-
acteristic 'onion skin' or 'zebra' appearance. These pathological 
features are also evident in heterozygous females. Deposits occur  
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Fig. (3). A. Two glomeruli, 1 with marked vacuolation of glomerular epithe-
lial cells (left) and 1 with moderately advanced sclerosis (right) (periodica-
cid-Schiff stain). B. Electron photomicrograph of glomerular epithelial cells 
showing intralysosomal concentric lamellar membranous inclusions typical 
of Fabry disease. (from Joe T.R. Clarke, Narrative Review: Fabry Dis-
ease.Ann Intern Med 2007. 
 
before the development of renal impairment. As patients age, the 
disease progresses in cells throughout the kidney, and is associated 
with increasing glycosphingolipid accumulation. 
 Clinical onset of the disease in hemizygous males usually oc-
curs during childhood or adolescence, with periodic crises of severe 
pain in the extremities (acroparesthesias), the appearance of the 
vascular cutaneous lesions (angiokeratoma), hypohidrosis, and the 
characteristic corneal dystrophy (Fig. 4). With increasing age, the 
major morbid symptoms of the disease result from the progressive 
infiltration of glycosphingolipid in the cardiovascular-renal system.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Characteristic cornea verticillata in Fabry disease. 
 
  Death usually occurs from renal, cardiac, or cerebral complica-
tions of the vascular disease. Prior to the availability of treatment 
by renal transplantation or dialysis, the average age at death for 
affected males was about 40 years. Heterozygous females, who may 
exhibit the disease in an attenuated form, are most likely to have 
only corneal opacities. Previously, the diagnosis of affected 
hemizygous males and heterozygous females was based on clinical 
findings and the levels of alpha-galactosidase A activity in easily 
obtained sources, e.g., plasma and isolated lymphocytes or granulo-
cytes. Because the gene encoding alpha-galactosidase A undergoes 
random X-inactivation, the expressed level of enzymatic activity in 
females heterozygous for the disease gene may vary significantly, 
thereby making accurate carrier detection difficult. With the advent 
of recombinant protein synthesis technology, enzyme replacement 
therapy has become a viable alternative to dialysis or renal trans-
plantation, previously the only available treatment options for end-
stage renal disease. 
 In a recent study [21] the pre- and post-treatment renal biopsies 
were analyzed from fifty-eight Fabry patients enrolled in a Phase 3 
double-blind, randomized, placebo-controlled trial followed by a 
six-month, open label, extension study of the recombinant human 
enzyme, alpha-galactosidase A (r-hlphaGalA), administered IV at 1 
mg/kg biweekly. 
 The purpose of this investigation was to detail the pathologic 
changes in glycosphingolipid distribution and the pattern of post-
treatment clearance in the kidney. Baseline evaluations revealed 
Gb-3 accumulations in nearly all renal cell types including vascular 
endothelial cells, vascular smooth muscle cells, mesangial cells and 
interstitial cells, with particularly dense accumulations in podocytes 
and distal tubular epithelial cells. After 11 months of r-halphaGalA 
treatment there was complete clearance of glycolipid from the en-
dothelium of all vasculature as well as from the mesangial cells of 
the glomerulus and interstitial cells of the cortex. Moderate clear-
ance was noted from the smooth muscle cells of arterioles and small 
arteries. Podocytes (Fig. 5) and distal tubular epithelium also dem-
onstrated evidence for decreased Gb-3, although this clearance was 
more limited than that observed in other cell types. No evidence of 
immune complex disease was found by immunofluorescence de-
spite circulating anti-r-halphaGalA IgG antibodies. These findings 
indicate a striking reversal of renal glycosphingolipid accumulation 
in the vasculature and in other renal cell types, and suggest that 
long-term treatment with r-halphaGalA may halt the progression of 
pathology and prevent renal failure in patients with Fabry disease 
(Tables 7, 8, 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Gb-3 is cleared from podocytes. (A) Baseline biopsy, pre-
treatment. Gb-3appears as multiple, tight scroll-like figures that fill the 
cytoplasm of each podocyte. (B) Post-treatment. The scroll-like Gb-3 forms 
are looser and less numerous after treatment. Podocytes are outlined pre- 
and post-treatment for emphasis (magnification of A and B, 100 objec-
tive). (C) Electron microscopic image demonstrating the lamellar ultrastruc-
ture of the Gb-3 accumulation in podocyte cytoplasm at baseline (magnifi-
cation, 10,000). 
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Table 7. Scoring System for Gb-3 Accumulation/Clearance in Different Renal Cell Types 
Cell/tissue Score 
Glomerular endothelial cells 0 = None or trace accumulation  
Peritubular capillary endothelial cells 1 = Mild accumulation 
Arterial/arteriolar endothelial cells 
Vascular smooth muscle cells 
 2 = Moderate accumulation 
Podocytesa   3 = Severe accumulation 
DCT/collecting ductsa   
Mesangial cells: Gb-3  
accumulation 0 = No lipid granules 
Interstitial cells 1 = Minimal lipid granules 
Mesangial matrix 2 = Numerous lipid granules 
 0 = Normal mesangium 
 1 = Mild expansion 
 2 = Moderate expansion 
a For the podocytes and distal convoluted tubules (DCT)/collecting ducts, an increase (+), a decrease (-) or no change (0) response was collected for all post-baseline scores by com-
paring the baseline biopsy to a 5 or 11 month biopsy. Therefore, there are no absolute baseline values for these cell types, only relative values at 5 months and 11 months that reflect a 
comparison to the baseline. 
 
Table 8. Percentage of Patients Achieving Zero Scores
*
 (Percentages of Patients with a 1-3 Point Score Reduction, Including all 
Zero Scores, are Shown in Parentheses) 
   Score shift from baseline to 5 months Score shift from baseline to 11 months 
Renal cells evaluated TX group Baseline 5 months N  Baseline 11 monthsa  N  
Peritubular capillary endothelial cells Placebo 0% 0% (38%) 29 0% 100% (100%) 24 
  A-gal 3% 69% (86%) 29 0% 92% (96%) 25 
Glomerular capillary endothelial cells Placebo 0% 0% (31%) 16 0% 100% (100%) 21 
  A-gal 0% 100% (100%) 19 0% 100% (100%) 17 
Mesangial cells Placebo 0% 0% (19%) 16 0% 90% (100%) 21 
  A-gal 0% 100% (100%) 19 0% 100% (100%) 17 
Interstitial cells Placebo 0% 0% (0%) 24 0% 78% (91%) 24 
  A-gal 4% 71% (100%) 24 4% 100% (100%) 24 
Arterial/arteriolar endothelial cells Placebo 0% 0% (19%) 22 0% 87% (100%) 22 
  A-gal 10% 86% (100%) 21 9% 96% (100%) 22 
Vascular smooth muscle cells Placebo 0% 0% (10%) 22 0% 0% (86%) 22 
  A-gal 0% 10% (86%) 21 0% 0% (81%) 21 
The clearance of Gb-3 from multiple renal cell types was determined before and after enzyme replacement therapy. There were two groups of patients: (1) the placebo group received 
placebo for the first 5 months and then -galactosidase A for the remaining 6 months and (2) the A-gal group which received -galactosidase A for the entire 11 months. The per-
centage of patients who attained a zero score at each biopsy time point is displayed and the percentage of all patients who demonstrated a reduction in score, including all zeros, is in 
parentheses. Values are presented for both the placebo and treatment groups. For statistical purposes, it was necessary for each patient to have both a baseline score and a shift score 
(5 months or 11 months) for each cell type, in order to be included in this data set. Two baseline columns are presented; the "N" designates the number of paired scores available for 
each cell type (paired scores meaning baseline and 5 months, or baseline and 11 months). This permitted calculation of the statistical significance of the change in score from either 
baseline to 5 months, or from baseline to 11 months, when comparing the placebo and treated groups. This distinction was necessary because (1) some patients had a poorly preserved 
or missed biopsy at one of the time points, and (2) some biopsy specimens did not contain glomeruli and therefore those cells could not be evaluated at all time points. 
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Table 9  Percentage of Patients Achieving a Reduction in Gb-3 Relative to Baseline
*
 
   5 months  11 months
a
  
  TX group % N  % N  
Tubular epithelium Placebo 4% 24 78% 24 
  A-gal 25% 24 50% 24 
Podocytes Placebo 0% 16 23% 22 
  A-gal 5% 19 18% 17 
* Tubular epithelium and podocyte clearance were expressed as the percentage of patients attaining a relative reduction in the 5 month and 11 month biopsy. An increase (+), a de-
crease (-) or no change (0) response was collected for all post baseline scores by comparing the baseline biopsy to a 5 or 11 month biopsy. Therefore, there are no absolute baseline 
values for these cell types, only relative values at 5 months and 11 months that reflect a comparison to the baseline. A-gal represents patients treated with the recombinant human 
enzyme, -galactosidase A. 
 
 Furthermore, to determine the long-term safety and efficacy of 
recombinant human alpha-galactosidase A, an open-label, phase III 
extension study [22] was conducted, involving 58 patients who had 
classic Fabry disease and completed a 20-wk, double-blind, ran-
domized, placebo-controlled, phase III study of agalsidase beta and 
were transitioned to an extension trial to receive biweekly 1 mg/kg 
agalsidase beta for up to an additional 54 mo. Gb-3 accumulation 
was evaluated in the capillary endothelia of the skin, kidney, and 
heart. Renal function was assessed (Figs. 6, 7). By month 54, all 
patients with optional kidney biopsies (n=8) maintained complete 
Gb-3 clearance in renal capillary endothelial cells and multiple cell 
types. Continued, complete clearance of skin (thirty-one of thirty-
six) and heart (six of eight) capillary endothelium was demon-
strated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Globotriaosylceramide (Gb-3) clearance from kidney, heart, and 
skin capillary endothelium in all patients. Histologic specimens that were 
obtained at pretreatment, month 6, and month 54 (optional for kidney and 
heart) were evaluated for the presence of Gb-3. Results show that for the 
majority of patients, initial Gb-3 clearance (score of 0) seen at month 6 was 
maintained during the 54-mo treatment period. Numbers above bar graphs 
represent the number of patients with zero scores out of the total number 
evaluated. cap. endo., capillary endothelium. 
 
 Mean plasma Gb-3 levels remained decreased in the normal 
range. Median serum creatinine and estimated GFR remained stable 
(normal) in patients with renal data at month 54 (n=41). Six patients 
had renal disease progression; most (four of six) were older than 40 
yr and had significant proteinuria at baseline and evidence of scle-
rotic glomeruli pretreatment. Adverse events were generally mild 
and unrelated to treatment. The most common treatment-related 
adverse events were infusion-associated reactions, which decreased  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Median estimated GFR (eGFR; ml/min per 1.73 m2) over time. 
Patients in the “as treated” population maintained a stable median eGFR 
during the 54-mo treatment period, which was observed in both the pla-
cebo/agalsidase  and the agalsidase /agalsidase  treatment groups (left) 
as well as in the overall, combined population (right). 
 
 
 
Fig. (8). Electron micrographs of a typical heart specimen of a AFD related 
cardiomyopathy showing the completely destroyed myocardial architecture. 
Of note are the multilamellar myelin bodies of the Gb-3 deposits and the 
additional vacuolization of the myocardium( Courtesy of Prof. Kuhn, Bielle-
feld) 
 
over time. Long-term agalsidase beta therapy stabilizes renal func-
tion in patients without renal involvement at baseline, maintains  
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reduction of plasma Gb-3, and sustains Gb-3 clearance in capillary 
endothelial cells and multiple renal cell types. 
 The enzyme defect on the basis of AFD leads to progressive 
accumulation of glycosphingolipids (GL) in all kinds of cells, tis-
sues, organs, and body fluids. The clinical manifestations are very 
protean, the residual activity of alpha-Gal-A and/or different gene 
mutations might explain different phenotypes, but as yet these con-
cepts have not been proven. Usually, patients with AFD show 3 
clinical phases, more evident in men than in heterozygous women. 
The first phase (childhood and adolescence) is characterized by 
myalgia, arthralgia, acroparesthesia, fever, cutaneous angiokera-
tomas, and corneal opacities. The second phase is characterized 
mainly by renal involvement. In the third phase, severe renal im-
pairment and involvement of cerebrovascular and cardiovascular 
systems are present. The progression to end-stage renal disease 
(ESRD) is common in hemizygous males (3rd-5th decade of life); 
usually, death occurs because of cerebral and/or cardiovascular 
complications in patients undergoing chronic dialysis therapies. The 
survival of patients with AFD in dialysis is better than in diabetic 
patients, but it clearly is decreased compared with uremic patients 
with other nephropathies, despite a lower mean age of uremia (50 
versus 60 y). The outcome of kidney transplantation is similar to 
that found in other patients with ESRD, despite controversial issues 
published in the past. The use of a kidney donor with normal alpha-
Gal-A activity in the control of the metabolic systemic disease is 
unproven. The recurrence of GL deposits in the kidney graft has 
been documented rarely. The definitive treatment for AFD is en-
zyme replacement therapy with purified alpha-Gal-A produced by a 
genetically engineered human cell line or Chinese hamster oocytes: 
relatively short-term studies have shown a significant treatment. In 
the evaluation of early Fabry nephropathy, clinical assessments lack 
sensitivity, potentially delaying initiation of ERT [23] highlighting 
the utility of kidney biopsies as part of the baseline assessment. A 
similar scoring strategy was used for lupus nephritis [24] and focal 
segmental glomerulosclerosis [25]: [26]. Some authors [27] evalu-
ated disease-specific Gb-3 lesions and secondary effect on clinical 
outcome measures, alterations that occur in Fabry nephropathy [28] 
as well as any other form of CKD (e.g. arterial and glomerular scle-
rosis, and interstitial fibrosis). Interstitial fibrosis, global and seg-
mental sclerosis and podocyte inclusions were robustly scored. The 
latter parameter showed the highest degree of inter-individual 
agreement. The semi-quantitative scoring of interstitial fibrosis 
showed similar reliability when compared to the morphometric 
assessment. Other lesions (e.g. parietal epithelial cell inclusions, 
interstitial inflammation) could not be reliably scored with the cur-
rent approaches. 
 The development of a standardized scoring system of both dis-
ease-specific lesions, i.e. lipid deposition related, and general le-
sions of progression, i.e. fibrosis and sclerosis, showed a spectrum 
of histologic appearances even in early clinical stage of Fabry neph-
ropathy. These findings support the role of kidney biopsy in the 
baseline evaluation of Fabry nephropathy, even with mild clinical 
disease. The scoring system will be useful for longitudinal assess-
ment of prognosis and responses to therapy for Fabry nephropathy. 
AFD Vasculopathy and Cardiomiopathy  
 Fabry disease is an X-linked lysosomal storage disorder caused 
by deficiency of the enzyme alpha-galactosidase A and character-
ized by a progressive left ventricular hypertrophy mimicking the 
clinical phenotype of hypertrophic cardiomyopathy. 
 Although clinical features of the disease are mostly displayed in 
affected males, female carriers may suffer from Fabry related com-
plications as well. The principal clinical manifestations in Fabry 
disease consist of artery associated complications (such as cerebral 
disease and nephropathy), but the pathophysiology of this specific 
vasculopathy is unclear. Several studies indicate that the specific 
vascular lesions that are present in Fabry disease occur as a result of 
vascular dysfunction with major components being endothelial 
dysfunction, alterations in cerebral perfusion and a pro-thrombotic 
phenotype [29,30]. Possibly, other cardiovascular risk factors may 
contribute to enhanced athero-thrombogenesis and a worsening of 
arterial performance. Although some patients with Fabry disease 
may suffer from stroke by involvement of larger arteries, small-
vessel disease causes cerebral complications and probably contrib-
utes to complications of the kidney and the heart [31,32,33]. Con-
troversy exists whether the storage in the endothelial cells and the 
pro-thrombotic state are the origin of arterial damage or whether 
smooth muscle cell proliferation in the arterial media layer is the 
initiating step in the cascade that leads to Fabry vasculopathy 
[34,35]. Supraventricular and ventricular arrhythmias are com-
monly observed in older patients with cardiac hypertrophy and in 
the advanced stage of the disease [36,37]. A report [38] shows that 
ventricular arrhythmias in Fabry disease are caused by infiltration 
of cardiac conduction tissue that can be privileged with respect to 
working cardiomyocytes giving rise to occult ventricular arrhyth-
mias and sudden death even in young people. 
 Fabry cardiac involvement has several clinical manifestations 
(Table 10): concentric left ventricular hypertrophy without left 
ventricular dilation and severe loss of left ventricular systolic func-
tion, mitral and aortic valvulopathy, disorders of the atrioventricular 
conduction or repolarization, and compromised diastolic function. 
Differentiating Fabry disease from similar conditions is often quite 
straightforward, e.g., cardiac amyloidosis is often associated with 
low electrocardiographic voltages, and systemic symptoms are 
usually associated with hemochromatosis and sarcoidosis. How-
ever, sometimes second-level (genetic analysis, alpha-galactosidase 
levels) or invasive investigations, which can include endomyocar-
dial biopsy, are required (Fig. 8). 
 Diagnostic imaging techniques have been described, but they 
lack specificity. Echocardiographic imaging with tissue Doppler 
analysis and/or strain rate analysis can allow diagnosis of Fabry 
disease even before left ventricular hypertrophy becomes apparent. 
This review illustrates the techniques for staging cardiac involve-
ment and damage in Fabry disease and for the long-term follow-up 
of Fabry patients with or without cardiac involvement. Careful 
cardiac monitoring is especially important in elderly female carri-
ers, who often develop renal disorders and/or left ventricular hyper-
trophy as the only manifestations of their late Fabry disease. In 
some clinical series, Fabry disease was diagnosed in 12% of women 
with adult-onset hypertrophic cardiomyopathy. Cardiological prob-
lems and outcomes of enzyme replacement therapy, associated with 
or without other cardiological treatments, are also discussed. 
 From previous studies, it is known that the morphological hall-
marks of Fabry cardiomyopathy are LV hypertrophy and replace-
ment fibrosis, which are both consistent with the finding of reduced 
regional LV function. In male patients, the LV starts to hypertrophy 
during adolescence; this is accompanied by reduced longitudinal 
function. The hypertrophy in these male patients progresses quite 
fast and finally leads to replacement fibrosis. In contrast, the fixed 
linkage of hypertrophy and fibrosis seemed to be not applicable for 
female patients with Fabry disease, although in general the same 
hallmarks (i.e., hypertrophy, reduced regional myocardial function, 
and replacement fibrosis) can be detected in the hearts of most fe-
male patients with Fabry cardiomyopathy. Thus, it seems that in 
this cohort, the progression toward severe hypertrophy in female 
patients was prolonged because of the residual activity of alpha 
galactosidase A (caused by the random inactivation of the mutated 
or non-mutated X chromosome). This is in concordance with previ-
ous studies done by Goldman et al. [39] and Linhart et al. [40] 
showing that LV hypertrophy is more common in male than in fe-
male patients. However, despite the delayed development of hyper-
trophy, fibrosis seems to progress continuously. Niemann et al. [41] 
hypothesized that Fabry cardiomyopathy in female patients might  
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Table 10. Cardiac Investigations. [From C. Golfomitsos et al. 
Fabry Disease. March 2012 Br J Cardiol 2012] 
 
differ substantially from that in male patients and sought to prove 
this hypothesis in a large cohort consisting of 104 patients with 
Fabry disease. Fabry cardiomyopathy in male patients is character-
ized by left ventricular (LV) hypertrophy, impaired myocardial 
function, and subsequent progressive myocardial fibrosis. In con-
trast, the occurrence of these 3 cardiomyopathic hallmarks in fe-
male patients remains unknown. In 104 patients (58 females, age 42 
± 16 years; 46 males, age 42 ± 13 years) with genetically proven 
Fabry disease, LV hypertrophy, regional myocardial deformation 
and myocardial fibrosis were assessed by standard echocardiogra-
phy, strain rate imaging, and cardiac magnetic resonance (CMR) 
imaging-guided late enhancement (LE). In men, end-diastolic left 
ventricular wall thickness (LVWT) ranged from 6 to 19.5 mm [LV 
mass CMR 55 to 200 g/m(2)], and LE was never seen with LVWT 
<12 mm [LV mass <99 g/m(2)]. In contrast in female patients, 
LVWT ranged from 5 to 15.5 mm, LV mass ranged from 39 to 146 
g/m(2), and LE was already detectable with an LVWT of 9 mm 
[LV mass 56 g/m(2)]. When LV mass was examined in CMR, LE  
 
was detected in 23% of the female patients without hypertrophy 
(n=9), whereas LE was never seen in male patients with normal LV 
mass. LE was always associated with low systolic strain rate, but 
the severity of impairment was independent of LVWT in female 
patients (lateral strain rate in patients with LV hypertrophy with LE 
-0.7 ± 0.2 s(-1); patients without LV hypertrophy with LE -0.8 ± 
0.2 s(-1); p=0.45). In this study in contrast to male patients, the loss 
of myocardial function and the development of fibrosis do not nec-
essarily require myocardial hypertrophy in female patients with 
Fabry disease. Thus, in contrast to actual recommendations, initial 
cardiac staging and monitoring should be based on LV hypertrophy 
and on replacement fibrosis in female patients with Fabry disease 
(Figs. 9,10,11,12,13). 
 
 
 
 
 
 
 
 
 
Fig. (9). Distribution of LE Depending on LVWT in Female Patients With 
Fabry Disease: Each bar symbolizes a single patient. Patients showing late 
enhancement (LE) are green bars. The patients are shown in the order of 
their left ventricular wall thickness (LVWT), the y-axis displaying the 
amount of end-diastolic LVWT. The pink line indicates the border toward 
LV hypertrophy. Note that some female patients were already LE positive 
(green bars) without being hypertrophic. CMR: cardiac magnetic resonance. 
 
 
 
Fig. (10). Distribution of LE Depending on LVWT in Male Patients with 
Fabry Disease: Each bar symbolizes a single patient. Patients showing LE 
are green bars. The patients are shown in the order of their LVWT, the y-
axis displaying the amount of end-diastolic LVWT. The pink line indicates 
the border toward LV hypertrophy. Note that male patients are only LE 
positive if they have an LVWT 12 mm and that male patients develop a 
larger amount of LV hypertrophy compared with female patients (Fig. 9). 
Abbreviations as in (Fig. 9). 
 Furthermore, in a study by Weidemann et al. [42], similar to 
other studies on morphological abnormalities in Fabry disease, the 
typical finding of LV hypertrophy was frequently detected. The 
increase of myocardial wall thickness appears to be an early marker 
indicating definite morphological change as a consequence of gly-
cosphingolipid accumulation. The second typical morphological 
finding was late enhancement in the LV which is discussed as a 
marker for myocardial fibrosis. This study showed, in accordance 
with previous studies, that 50% of their patients had late enhance-
ment predominantly in the LV inferolateral wall. The underlying 
mechanism for this mainly intramural pattern of late enhancement 
is unknown. An ischemic pathology is unlikely since previous stud-
ies excluded coronary artery disease in this group of patients and 
ischemic necrosis usually starts at the subendocardium, finally in-
ducing a decrease in wall thickness in the chronic phase. It is 
known that LV work load is highest in the inferolateral wall. This 
might initiate development of myocardial fibrosis in these segments 
because a high work load may increase local wall stress. 
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Fig. (13). Echocardiographic and CMR Images of a Female Patient without 
LV Hypertrophy but with LE (A) Short-axis echocardiographic view. (B) 4-
chamber echocardiographic view. The LV cavity is marked with LV. The 
images clearly show that no LV hypertrophy is present. (C) Short-axis view 
of the same patient using the LE technique by CMR. (D) 4-chamber CMR 
view. The arrows indicate LE in thelateral wall. 
 
 In Anderson-Fabry disease (AFD), a progressive deposition of 
sphingolipids is reported in different organs. A recent study [43] 
applied 1H magnetic resonance spectroscopy (MRS) to investigate 
the myocardial lipid content. In patients proven AFD, 1H MRS of 
the heart was acquired in the same examination as routine cardiac 
cine and late enhancement MR imaging. Healthy volunteers (n = 
11) without history of cardiac disease served as control (CTL). 
Myocardial triglycerides in vivo were quantified in 1H MRS. Left 
ventricular (LV) ejection fraction (EF) and late enhancement were 
assessed for the determination of LV systolic function, and onset or 
absence of myocardial fibrosis. Results: all 1H MRS revealed reso-
nances for intramyocardial triglycerides. Clinical parameters, e.g. 
EF (PTS 64 ± 2 % vs. CTL 61 ± 1 %) were similar in PTS and CTL 
or showed a non-significant trend (LV mass). Apart from a single 
patient with elevated myocardial triglycerides, no significant impact 
of Fabry disease on the triglyceride/water resonance ratio (PTS 0.47 
± 0.11 vs. CTL 0.52 ± 0.11 %) was observed in this patient cohort. 
On this basis authors conclude that a comprehensive cardiac evalua-
tion of morphology, function as well as metabolism in Fabry PTS 
with suspected cardiac involvement is feasible in a single examina-
tion. No significant effect of myocardial triglyceride deposition 
could be observed in patients. The remarkably high myocardial 
triglyceride content in one patient with advanced FD warrants fur-
ther studies in PTS with an extended history of the disease. 
 AFD disease presents as a vascular disease, with cerebral, car-
diac, and renal complications. Rombach et al. [44] measured ca-
rotid intima-media thickness (IMT), brachial flow-mediated dilation 
(FMD), pulse wave velocity, and advanced glycation end products 
in 57 classically affected patients (22 men and 35 women), 55 
healthy matched controls (20 men and 35 women), and 10 atypical 
Fabry disease patients (5 men and 5 women). Most patients re-
ceived enzyme replacement therapy. In classically affected male 
patients, brachial FMD was decreased (2.9% [95% CI, 0.8% to 
7.9%] versus 5.9% [2.1% to 8.5%] in controls; P=0.01), and carotid 
 
 
 
Fig. (11). Distribution of LE Depending on Age in Female Patients with Fabry Disease. 
Each bar symbolizes a single patient. Patients showing LE are green bars. The patients are sorted in the order of their age. The y-axis displays the amount of 
end-diastolic LVWT. The pink line indicates the border toward LV hypertrophy. Note that some younger female patients who were nonhypertrophic already 
showed LE and some older patients did not show cardiac involvement at all. Abbreviations as in (Fig. 9). 
 
 
 
Fig. (12). Distribution of LE Depending on Age in Male Patients with Fabry Disease 
Each bar symbolizes a single patient. Patients showing LE are green bars. The patients are sorted in the order of their age. The y-axis displays the amount of 
end-diastolic LVWT. The pink line indicates the border toward LV hypertrophy. Note that the onset of LE according to age in male patients was earlier than 
that in female patients. Abbreviations as in (Fig. 9). 
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IMT was increased (0.67 mm [95% CI, 0.50-0.96 mm] versus 0.59 
mm [95% CI, 0.40-0.76 mm] in controls; P=0.01). In women and 
atypical patients these vascular parameters were comparable with 
controls. Pulse wave velocity was not different; advanced glycation 
end products were only slightly increased in atypical patients. In 
classically affected women, a small increase in lysoGb3 was asso-
ciated with an increase in IMT independent of age. In the classi-
cally affected men, all with increased IMT and high levels of 
plasma lysoGb3, lysoGb3 levels did not add to a higher IMT, sug-
gestive of a ceiling effect. For FMD, elevated lysoGb3 levels (>7 
nmol/L) contributed to a 2.9% lower FMD independent of age and 
sex (P=0.02). Increased carotid IMT and decreased brachial FMD 
occur in classic Fabry disease, which is associated with plasma 
lysoGb3 level independent of age and sex.  
 On this basis it’s possible to underline that cardiovascular com-
plications due to the accumulation of globotriaosylceramide in car-
diac cells occur in almost all patients affected by Anderson-Fabry 
disease. Cardiac manifestations include left ventricular hypertro-
phy, mitral regurgitation, conduction disturbances and myocardial 
ischaemia. We recently reported a case of Fabry's disease diagnosed 
several years after the onset of early cardiac symptoms [45] (Figs. 
14, 15,16). 
CNS INVOLVEMENT 
 The neurological manifestations of Fabry disease include both 
peripheral nervous system and CNS involvement, with globotriao-
sylceramide accumulation found in Schwann cells and dorsal root 
ganglia together with deposits in CNS neurones. The main in-
volvement of the CNS is attributable to cerebrovasculopathy, with 
an increased incidence of stroke. The abnormal neuronal accumula-
tion of glycosphingolipid appears to have little clinical effect on the 
natural history of Fabry disease, with the possible exception of 
some reported mild cognitive abnormalities. The pathogenesis of 
Fabry vasculopathy remains poorly understood, but probably re-
lates, in part, to abnormal functional control of the vessels, secon-
dary to endothelial dysfunction as a consequence of -galactosidase 
A deficiency (Fig. 17). 
 Obstructive vasculopathy, either primarily due to accumulation 
of glycolipid or secondary to consequent inflammation and con- 
 
 
 
 
 
 
 
Fig. (14). Enzymatic assay revealed a reduced plasma alpha galactosidase A activity: 0.4nmol/ml/h, which is a typical value for hemizygous Fabry patient. 
Genetic DNA sequence analysis detected the presence of a point mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (15). ECG: showing electrical signs of left ventricular hypertrophy, reduced PR interval, LBBB, alterations in the ventricular repolarization phase in an-
terolateral leads, in a 55-year-oldmale patient with AFD. 
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Fig. (16). Echocardiography shows left ventricular hypertrophy, moderate-
to-severe systolic dysfunction; left ventricular endocardium appears hypere-
chogenic. 
 
 
 
 
 
 
 
 
Fig. (17). Electron micrograph showing the vascular endothelium of a small 
vessel from a patient with Fabry disease. Progressive accumulation of sub-
strate leads to ischemia and eventual vessel infarction. (From R.J. Desnick, 
MD, Phd) 
 
founding vascular risk factors, may develop in response to abnor-
mal endothelial and vessel wall function, similar in some respects to 
that observed with accumulation of cholesterol-laden lipids during 
atherosclerosis. Involvement of the peripheral nervous system af-
fects mainly small A and C fibres, and is probably causally related 
to the altered autonomic function and neuropathic pain found in 
Fabry disease. Other related neurological problems include hypo-
hidrosis and other abnormalities associated with nervous system 
dysfunction. 
 A recent study [46] described CNS involvement in a group of 
Italian patients with AFD. Clinical and brain MRI data of 43 pa-
tients with AFD (25 men, 41.94+/-10.83 years old and 18 women, 
52.48+/-17.50 years old) were analysed retrospectively. 17 male 
patients and 7 female patients were under treatment with enzyme 
replacement therapy (ERT). All 43 patients had signs or symptoms 
of AFD. 16 men (64%) and 13 women (72%) demonstrated CNS 
involvement, although with varying severity. Overall, 6 men and 5 
women had suffered from cerebrovascular accidents with an age at 
onset of 33.64+/-13.65 years and 53.68+/-11.71 years, respectively. 
Brain MR images were abnormal in 16/25 men and in 13/16 
women. During CNS monitoring, some patients receiving ERT 
(5/17 men and 2/6 women) demonstrated neurological deteriora-
tion, especially those who had presented with cerebrovascular dis-
ease already before starting ERT. This study demonstrated a high 
frequency of CNS involvement in homozygous and heterozygous 
AFD patients, often characterised by early age at onset and abnor- 
 
mal brain MRIs. At present, ERT is widely used; however, potential 
beneficent effects may be disguised by the progression of irreversi-
ble pathology in short-term follow-up. Therefore, primary and sec-
ondary prophylaxes of cerebrovascular disease are extremely im-
portant. Along with progressive renal and cardiac dysfunction, 
stroke is a major and often life-threatening burden of the disease. 
Cerebral vasculopathy, confirmed by neuropathological, neuroradi-
ological, and functional studies, occurs commonly and leads to 
ischaemic cerebrovascular events at an early age. Fabry's disease is 
an X-linked disease and women have been regarded as only mildly 
affected carriers. However, research has shown a high prevalence of 
ischaemic stroke and transient ischaemic attacks, along with imag-
ing evidence of CNS involvement, in female patients with the dis-
ease, which suggests that at least in a subgroup of clinically af-
fected women the severity of CNS disease is comparable to that in 
men. These new findings should be replicated in larger samples. 
Brain structural changes and CNS involvement in the disease need 
to be monitored carefully in follow-up studies to broaden our 
knowledge of the course of neurobiological changes and to identify 
potential effects of enzyme-replacement therapy, which is already 
showing some benefit in cardiac and renal dysfunction in the dis-
ease. On this basis a diagnosis of Fabry's disease should always be 
considered in young patients who have had a stroke. Neutral gly-
cosphingolipides (esp. Gb3) accumulate in lysosomes of several 
tissues, particularly in vascular endothelium and smooth muscle 
cells. Cerebral manifestations that might be mainly due to progres-
sive cerebrovascular dysfunction, are one major and often life-
threatening burden of the disease. We reviewed the present litera-
ture concerning brain structural alterations in FD and discussed the 
possibly relevant underlying pathophysiological aspects of these 
disturbances. Cerebrovascular events (TIA, stroke) occur in FD at a 
rather early age. In female FD patients who were considered to be 
less affected "carriers" for a long time, the prevalence of cere-
brovascular events seems to be at last as high as in male patients. In 
structural imaging white matter lesions (WML) can be found fre-
quently even in young FD patients. Different pathophysiological 
aspects of cerebral angiopathy and WML development are dis-
cussed against the background of current concepts (e.g. accumula-
tion of Gb3 in vascular endothelium with consecutive cell prolifera-
tion and luminal stenosis, acceleration of focal intravasal pressure 
and disturbances of vascular auto-regulation). Pathological increase 
of pulvinar signal in T1-weighted MRI has also been described in 
FD. This finding was assumed to be caused by calcification as a 
consequence of disturbed local circulation. To enhance our knowl-
edge about the relevant neurobiological processes the some authors 
propose a more sensitive and early detection of brain structural 
changes in FD. New brain structural MRI methods such as diffu-
sion-tensor imaging could provide a pattern of ultrastructural 
changes even in young patients without visible WML. This strategy 
could be as well useful for quantification of possible effects of the 
enzyme replacement therapy on brain structural alterations in FD. 
Based on recent data a systematic FD-screening by measuring Gb3 
in urine of young patients with cryptogenic stroke should be dis-
cussed. Basically in such cases AFD should be clinically consid-
ered. 
 A study conducted by Marino et al. [47] assessed structural and 
metabolic brain changes in subjects affected by Fabry disease (FD) 
or carrying the disease mutation (Table 11; Fig. 18).  
 Previous MR studies have shown structural and metabolic brain 
abnormalities in FD patients. It is not clear, however, whether tissue 
damage can be seen in both the brains of hemizygous and heterozy-
gous and whether quantitative MR metrics are useful to monitor 
disease evolution. Authors studied 4 males and 4 females with FD. 
Each subject underwent brain proton MRI/MR spectroscopic imag-
ing (MRSI) examinations to obtain measures of total brain volumes, 
total brain lesion volumes, magnetization transfer ratios (MTr) in  
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Fig. (18). A: Brain MRI(Flair)of a 54 year-old female patient with AFD: 
multifocal silent leucoencephalopathy. B: Brain MRI(T1) of a 36 year-old 
male patient with AFD: lacunar infarction and cerebral atrophy 
 
WM and central brain levels of N-acetylaspartate (NAA) to creatine 
(Cr). A second MR examination was performed in five subjects 
after 2 years. Focal WM lesions were found in 2 males and 1 fe-
male. The MTr values were always low in the WM lesions of FD 
subjects (p < 0.001) and also were low in the normal-appearing 
WM of 2 affected males. Total brain volumes were never decreased 
in FD subjects. Brain NAA/Cr values were significantly (p = 0.005) 
lower in FD subjects than in normal controls and correlated closely 
with Rankin scale measures (r = -0.79). On follow-up examinations, 
no significant MR changes were found. However, the small changes 
in NAA/Cr correlated closely with changes in Rankin scores (r = -
0.86). Subtle structural and metabolic tissue damage can extend 
beyond WM lesions in FD subjects. Diffuse brain NAA/Cr decrease 
can be found in FD subjects in relation to the degree of their CNS 
involvement and its evolution over time. 
 Nevertheless in a recent clinical, neuropathological and neuro-
chemical study [48] of a case of Anderson-Fabry's disease the neu-
ropathological examination is dominated by severe alterations in 
the cerebral vessels due to glycolipid deposits on the walls, with 
reduction or occlusion of the lumen. This is correlated with secon-
dary ischaemic foci scattered throughout the cortex as well as 
through the white matter. In addition, the cells of the cerebral cor-
tex, thalamus, basal ganglia, amygdala, cerebellar and olivary nu-
clei show a marked accumulation of lipofuscin. Biochemical ex-
amination reveals a threefold increase in galactolipids due to the 
specific alpha-galactosidase deficiency. Cholesterol is reduced sec-
ondarily to ischaemic myelin damage. Glycosaminoglycans uronic 
acid is increased in cytosol and membrane-bound fractions which 
could be related to reactive gliosis. Glycoprotein sugars show a 
decrease in N-acetyl-neuraminic acid and fucose as well as an in-
crease in hexosamines and hexoses in membrane-bound fraction, 
while in cytosol fraction all sugars are increased. This suggests that 
the alpha-galactosidase deficiency can alter not only the glycolipid 
but also the glycoprotein metabolism, resulting in a higher presence 
of hexosamines and hexoses-rich glycoproteins. 
 Furthermore, ischemic stroke is related to inflammation [49,50, 
51,52] and arterial stiffness [53,54] and no study had addressed this 
relationship in patients with AF disease and cerebrovascular dis-
ease, so this topic could represent a possible future research line.  
SKIN INVOLVEMENT 
 The diagnosis of Fabry disease is made in hemizygous males 
after the detection of the presence of angiokeratomas (Fig. 19A, B), 
irregularities in sweating, edema, scant body hair, painful sensa-
tions, and of cardiovascular, gastrointestinal, renal, ophthalmologic, 
phlebologic, and respiratory involvement. A deficiency of alpha-gal 
A in serum, leukocytes, tears, tissue specimens, or cultured skin 
fibroblasts further supports the diagnosis in male patients. Since 
heterozygous women show angiokeratomas in only about 30% of 
 
Table 11. CNS Involvement: Clinical Features of the 43 Patients with AFD 
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Fig. (19) A. Skin biopsy (light microscopy): histologically, the typical skin 
lesion is a small superficial angioma caused by cumulative damage of the 
vascular cells of the dermis with vessel dilation.Courtesy: Dr Juan M. 
Politei Buenos Aires, Argentina. 
 
 
 
Fig. (19). B. Angiokeratoma in a 28-year-old male patient with AFD. Angi-
okeratomas are small, raised, dark-red spots that increase in number and size 
with age and can occur singly or in clusters. They are typically found on the 
lower back, buttocks, groin, flanks and upper thighs but their distribution 
may be restricted to a limited area, such as the umbilicus. 
 
cases and may have alpha-gal A levels within normal range, genetic 
analysis is recommended. 
 When cutaneous and mucous glands are affected, restrictions 
may be required with regard to the time spent in a warm climate 
and the amount time spent working or on sporting activities, and 
may necessitate the use of topical and systemic antiperspirant 
agents, and topical application of artificial lacrimal fluid and saliva, 
respectively. For the future, new treatment modalities, including 
enzyme replacement therapy, substrate deprivation strategies, and 
gene therapy offer extraordinary options for the cutaneous and vis-
ceral lesions in patients with Fabry disease.  
 In Anderson-Fabry disease lysosomal deposits of ceramide 
trihexoside have been repeatedly documented in a wide range of 
tissues, including those found in angiokeratoma, the characteristic 
[55] cutaneous lesion which allowed the definition of Fabry dis-
ease. In a recent study authors investigated whether there was any 
difference in the amount of dermal lysosomal storage in males and 
females, thus accounting for the difference in clinical severity of 
both groups. For that purpose, with electron microscopy and quanti-
tative methods, they studied the extent of lysosomal deposits in 
dermal fibroblasts of normal-appearing skin in six females and nine 
men, enzymatically and genetically proven as to have Fabry dis-
ease, and results were compared. These results indicate a statisti-
cally significant difference between the two groups regarding both 
the percentage of dermal fibroblasts bearing stored material, and the 
storage surface occupied in 100 fibroblasts per case.  
 In a study by Orteu et al. [56] authors ascertained the preva-
lence and nature of cutaneous manifestations in patients with Fabry 
disease and relate these to the severity of systemic manifestations of 
the disease. They have documented the dermatological features of 
this disease with reference to data from 714 patients (345 males, 
369 females) registered on the Fabry Outcome Survey (FOS), a 
multicentre European database. Authors confirmed that the com-
monest disease manifestation is angiokeratoma. Overall, 78% of 
males and 50% of females had one or more dermatological abnor-
mality, the commonest being angiokeratoma (66% males, 36% 
females), hypohidrosis (53% males, 28% females), teleangectasia 
(23% males, 9% females) and lymphoedema (16% males, 6% fe-
males). They demonstrate for the first time that the presence of 
cutaneous vascular lesions correlates with the severity of the sys-
temic manifestations of the disease (pain, renal failure, cardiac dis-
ease, premature cerebrovascular disease) as assessed by a severity 
scoring system. Although the condition is X linked, there is a sur-
prisingly high prevalence of abnormalities in females. 
 The FOS database is a useful epidemiological tool in establish-
ing the variety and relevance of cutaneous manifestations in Fabry 
disease. The present study confirms that the presence of dermatol-
ogical manifestations appears to be a marker of greater severity of 
systemic disease, which emphasizes the importance of the derma-
tological assessment of these patients. 
AFD AS A MULTIORGAN DISEASE, POTENTIAL GE-
NETIC AND CIRCULATING MARKERS OF MULTIOR-
GAN INVOLVEMENT: CONCLUSIONS  
 Fabry disease is a rare lysosomal storage disorder caused by the 
deficient activity of the lysosomal enzyme alpha-galactosidase A. 
The resultant storage of undegraded glycolipids leads to the pro-
gressive development of potentially life-threatening manifestations 
affecting multiple organ systems in the body. The Mainz Severity 
Score Index (MSSI) (Table 12), a scoring system for patients with 
Fabry disease has been proven to be representative in patients with 
'classic' Fabry disease and may be useful for monitoring clinical 
improvement in patients receiving enzyme replacement therapy. 
The MSSI of patients with AFD was significantly higher than that 
of patients with other severe debilitating diseases. In a recent study 
by Whymbra et al. [57] the MSSI indicated that, although more 
men than women had symptoms classified as severe, overall, the 
median total severity scores were not significantly different be-
tween male and female patients. One year of ERT with agalsidase 
alfa led, in all patients, to a significant (p < 0.001) reduction in 
MSSI score (by a median of nine points).  
 Some authors conducted a study [58] that showed that the MSSI 
score may be a useful, specific measure for objectively assessing 
the severity of AFD and for monitoring ERT. Fabry disease is a 
multisystem disorder with phenotypic heterogeneity only partially 
explained by genotype. Elevated interleukin-6 (IL-6) plasma levels 
and C-reactive protein (CRP) serum levels are associated with in-
creased risk and worse outcome of ischaemic events, a serious 
prognostic sign in Fabry disease. In this study 56 patients (34 
hemizygous males, 22 females; 5 children) were studied. A 
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Table 12. The Mainz Severity Score Index (MSSI) and the Fabry Outcome Survey adaptation of the Mainz Severity Score Index 
(FOS-MSSI). 
 General score  Neurological score 
Sign/symptom Rating 
MSSI 
score 
FOS-MSSI 
score 
Adaptation to signs 
and symptoms Sign/symptom Rating 
MSSI 
score 
FOS-MSSI 
score 
Adaptation to signs 
and symptoms 
Characteristic facial 
appearance 
No 0 -  Tinnitus No 0 0  
 Yes 1 -   Mild 1 1 Any 
Angiokeratoma None 0 0   Severe 2 -  
 Some 1 1.5 Any Vertigo No 0 0  
 Extensive 2 -   Mild 1 1 Any 
Oedema No 0 0   Severe 2 -  
 Yes 1 1  Acroparaesthesia No 0 0  
Musculoskeletal No 0 0   Occasional 3 4 Pain attacks 
 Yes 1 1   Chronic 6 6 Chronic pain 
Cornea verticillata No 0 0  Fever pain crisis No 0 -  
 Yes 1 1   Yes 2 -  
Diaphoresis Normal 0 0  Cerebrovascular No 0 0  
 Hypo/hyper 1 1   Ischaemic lesions (in 
MRI/CT) 
1 3  
 Anhidrosis 2 2   TIA/migraine etc. 3 6 TIA, PRIND 
Abdominal pain No 0 0   Stroke 5 -  
 Yes 2 2  Psychiat-
ric/psychosocial 
    
Diarrhoea/constipation No 0 0  Depression No 0 0  
 Yes 1 1   Yes 1 1  
Haemorrhoids No 0 0  Fatigue No 0 -  
 Yes 1 1   Yes 1 -  
Pulmonary No 0 0  Reduced activity 
level 
No 0 -  
 Yes 2 2 Breathing difficulties  Yes 1 -  
New York Heart No 0 0       
Association (NYHA) 
classification*  
Class I 1 -       
 Class II 2 2 Angina      
 Class III 3 -       
 Class IV 4 -       
Maximum score  18 13.5  Maximum score  20 15  
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 Cardiovascular score  Renal score 
Sign/symptom Rating 
MSSI 
score 
FOS-MSSI 
score 
Adaptation to signs 
and symptoms Sign/symptom Rating 
MSSI 
score 
FOS-MSSI 
score 
Adaptation to signs 
and symptoms 
Changes in cardiac 
muscle thickness 
No 0 0  Evidence of renal 
dysfunction 
No proteinuria 0 0  
 Thickening of 
wall/septum 
1 -   Proteinuria 4 4 Haematuria/proteinuria 
 LVH seen on ECG 6 6   Tubular dysfunc-
tion/low GFR or 
creatinine clearance 
8 8 Renal failure 
 Cardiomyopathy (< 
15 mm) 
8 10 Heart failure  End-stage renal 
failure (serum creatin-
ine levels > 3.5 
mg/dl) 
12 -  
 Severe cardiomy-
opathy (> 15 mm) 
12 -   Dialysis 18 18 Dialysis/transplantation 
Valve insufficiency No 0 0       
 Yes 1 1 Valve disease      
ECG abnormalities No 0 0       
 Yes 2 2 Conduction abnor-
malities and ar-
rhythmia 
     
Pacemaker No 0 0       
 Yes 4 4 Surgery      
Hypertension No 0 0       
 Yes 1 1       
Maximum score  20 18  Maximum score  18 18  
*Limitation on physical activity according to NYHA classification is as follows. Class I: none; ordinary physical activity does not cause undue fatigue, palpitation, dyspnoea or angi-
nal pain, but echocardiography reveals heart involvement. Class II: slight; comfortable at rest, but ordinary physical activity results in fatigue, etc. Class III: marked; comfortable at 
rest, but less than ordinary physical activity causes fatigue, etc. Class IV: unable to carry out any physical activity without discomfort; symptoms of cardiac insufficiency or of anginal 
syndrome may be present even at rest and physical activity increases discomfort. 
CT, computed tomography; ECG, electrocardiography; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; PRIND, prolonged 
reversible ischaemic neurological deficit; TIA, transient ischaemic attack. 
 
promoter polymorphism -174G > C of the IL-6 gene associated 
with serum IL-6 levels was compared with the Mainz Severity 
Score Index (MSSI) in patients with Fabry disease. CRP levels and 
polymorphism 1059 G > C were evaluated as markers of inflamma-
tion to ascertain the possibility of an inflammatory mechanism of 
IL-6. Nonparametric ANOVA, Fisher's exact, Bonferroni, and 
Hardy-Weinberg (HW) statistics were used. 
 Significant correlation existed between all sub-scores of the 
MSSI and IL-6 genotypes in females but only with three MSSI sub-
scores for males. The IL-6 C/C genotype was significantly corre-
lated with the neurological, general and total MSSI sub-scores, 
generally twofold higher. There were no statistically significant 
correlations with CRP levels/polymorphisms and MSSI sub-scores 
nor with IL-6 polymorphisms. CRP levels decreased after ERT in 
patients with IL-6 G/G or G/C genotypes but increased in patients 
with C/C (p = 0.003). 
 The prevalence of the IL-6 C allele significantly influences 
MSSI, i.e. clinical severity, especially in females. This is unrelated 
to IL-6 as a pro-inflammatory marker as demonstrated by lack of 
correlations with CRP levels and genotypes. IL-6 -174 polymorphic 
C allele may be a prognostic marker in Fabry disease, especially in 
females, may be a expression of the multiorgan disease and proba-
bly ERT-related treatment effects. 
 Another study [59] evaluated functional gene polymorphisms of 
key pro- and anti-inflammatory cytokines and to correlate them to a 
clinical score to assess the potential role of inflammation in  
 Fabry disease. Genotyping for IL-10[819C/T; -592C/A]; IL-
1beta[+3954 C/T; -511C/T]; IL-1alpha[-889C/T]; and TNF-alpha[-
308G/A] was performed in 76 patients and correlated with MSSI 
sub-scores and with enzyme (alpha-galactosidase A) levels. Fifty, 
normal, age- and sex-matched volunteers were also genotyped. Of 
76 patients, 31 (41%) were males and 45 (59%) were females. 
There was no correlation between enzyme levels and any cytokine 
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levels. Statistically significant differences were found in prevalence 
of TNF-alpha [-308G/A] genotypes: 84% GG in patients versus 
63% GG in controls (p = 0.038) and for IL-1alpha [-889C/T] geno-
types: 94% CC in patients versus 21% CC in controls (p < 0.001). 
Statistically significant differences were found in the ratio between 
the two polymorphisms of IL-10 (p < 0.0001), between the two 
polymorphisms of IL-1beta (p = 0.001); between IL-1alpha [-
889C/T] and IL-1beta [3954C/T] (p = 0.002); and between IL-10[-
592C/T] and IL-1beta [3954C/T] (p = 0.041). Correlations between 
TNF-alpha [-308G/A] and both kidney and neurological MSSI sub-
scores (both: p = 0.06) and between IL-10[-819C/T] and the MSSI 
neurological score (p = 0.03) were noted (Tables 13, 14,15). 
 The majority of patients with Fabry disease have therefore a 
profile of low TNF-alpha (increased frequency of GG genotype of 
the TNF-alpha polymorphism), high IL-10 production (preponder-
ance of the C allele of the wild type or heterozygous state for the 
polymorphisms of IL-1, but simultaneously increased production of 
the pro-inflammatory cytokines IL-1beta and IL-1alpha usually 
associated with a preponderance of the C allele of the wild type or 
heterozygous state for the polymorphisms of IL-1beta and of IL-1 
alpha. Authors speculated that sequence variations of important 
inflammatory genes of the interleukin inflammatory family are 
associated with differential effects in Fabry disease, and with in-
creased sample size, haplotype blocks might be constructed. 
 Fabry syndrome is a genetic disease related to changes on the X 
chromosome. Its complex clinical presentation and diverse symp-
tomatology is caused by deficient activity of lysosomal hydrolase 
alpha-galactosidase enzyme. Defect in the basic alpha-galactosidase 
molecule implies genetic change, which can be a predisposing fac-
tor for the development of atypical and typical forms of this genetic 
disease. Clinical manifestation and hemizygous symptomatology 
were the evidence of metabolic and genetic irregularity, typical 
clinical presentation of Fabry disease. Many authors report general-
ized vasculopathy as a basic characteristic of Fabry disease and a 
causative factor of multiorgan changes. Some authors indicate that 
persons with diagnosed asymmetric hypertrophy of the left ventri-
cle have decreased alpha-galactosidase. Cardiac complications, 
coronary disease, and acute myocardial ischemia are often present 
in cases of Fabry disease, frequently causing death in such patients. 
Characteristic central nervous system symptoms with skin-burning 
sensation and paresthesia were also present. Cerebrovascular com-
plications were caused by changes on small blood vessels. Clinical 
signs of renal failure were nonspecific, and the diagnosis was based 
on extrarenal symptoms. Initial renal manifestations were insignifi-
cant as asymptomatic proteinuria and microhematuria, due to was 
referred to further examination. The level of alpha-galactosidase 
was significantly decreased. The severity and progression of this 
disease depends on the level of alpha-galactosidase enzyme in se-
rum and its catabolic effect.  
 The major debilitating manifestations of Fabry disease result 
from the progressive accumulation of globotriaosylceramide in the 
vascular endothelium, leading to ischemia and infarction, especially 
in the kidney, heart, and brain. The ischemia and infarction of small 
vessels are primarily due to vascular occlusion; however, evidence 
for a prothrombotic state has recently been published. In addition, 
early and substantial deposition of globotriaosylceramide occurs in 
podocytes, leading to proteinuria and, with age, in cardiomyocytes, 
causing cardiac hypertrophy and conduction abnormalities. 
 Patients are generally divided into two major groups on the 
basis of the absence or presence of residual alpha-Gal A activity: 
classic disease and milder, later-onset, atypical variants. With the 
availability of enzyme replacement therapy, prompt diagnosis and 
treatment of Fabry disease have assumed new importance. There is 
no comparable alternative to enzyme replacement therapy for this 
devastating, progressive disease. Future research should address the 
development of protocols for early diagnosis as well as optimal 
enzyme protocols for reversal, maintenance, and prevention of the 
underlying pathology of Fabry disease, especially for children, 
patients with compromised renal function, and those with cardiac 
disease. Enrollment of all patients in a Fabry disease registry is 
encouraged to increase knowledge of the natural history and com-
plications of the disease and the efficacy of treatment regimens. The 
Fabry Registry is a global observational research platform estab-
lished to define outcome data on the natural and treated course of 
this rare disorder. Participating physicians submit structured longi-
tudinal data to a centralized, confidential database. A recent report 
[60] describes the baseline demographic and clinical characteristics 
of the first 1765 patients (54% males (16% aged < 20 years) and 
46% females (13% < 20 years)) enrolled in the Fabry Registry (Ta-
bles 16, 17, 18). The median ages at symptom onset and diagnosis 
were 9 and 23 years (males) and 13 and 32 years (females), respec-
tively, indicating diagnostic delays in both sexes. Frequent present-
ing symptoms in males included neurological pain (62%), skin 
 
Table 13. Significant Differences in Inflammatory Gene Allele Distributions Between Patients with Fabry Disease Versus Controls 
Polymorphic variant Genotype Patients Controls p value 
 TNF- [-308] GG 84% 63% 0.038 
 IL-1 [-889] CC 94% 21% <0.001 
 
Table 14. Significant Differences Between Two Polymorphic Variants or with an MSSI Sub-Score 
Polymorphic variant Polymorphic variant/score p value 
 IL-10 [819]  IL-10 [-592] <0.0001 
 IL-1 [3954]  IL-10 [-592] 0.041 
 IL-1 [3954]  IL-1 [511] 0.001 
 IL-1 [-889]  IL-1 [3954] 0.002 
 IL-10 [819]  Neurological MSSI score 0.033 
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Table 15. Trends to Significant Difference Between Two Polymorphic Variants or with an MSSI Sub-Score 
Polymorphic variant Polymorphic variant/score p value 
 IL-10 [819]  TNF- [-308] 0.088 
 IL-10 [819]  IL-1 [3954] 0.069 
 IL-1 [-889]  TNF- [-308] 0.095 
 TNF- [-308]  Renal MSSI score 0.062 
 TNF- [-308]  Neurological MSSI score 0.064 
 
Table 16. Age at Onset and Types of Fabry Disease Symptoms 
 Males ( n=713) Females( n=430) 
Organ system Median age at onset 
(years) 
Percentage of males with 
symptom 
Median age at onset 
(years) 
Percentage of females with 
symptom 
Overall  9  13  
Neurological  9 67 10 47 
Neurological: pain 9 62 10 47 
Neurological: other 8 12 12 12 
Skin  9 31 17 12 
Ophthalmological  9 11 16 12 
Gastroenterological 8 19 14 13 
Respiratory  11 3 30 2 
Renal  20 17 28 11 
Cardiovascular  12 13 32 10 
Cerebrovascular  10 5 26 4 
 
Table 17. Age at First Clinical Event 
  Fabry registry patients 
Clinical event  Males (n=910) Females (n=775) 
Renal event  % of patients 13 2 
 Age(SD) 38.5(11) 37.3(10) 
 MEDIAN(RANGE) 38(14-79) 38(17-59) 
Cardiovascular event % of patients 19 14 
 Age(SD) 39.0(12) 47.6(13) 
 Median(range) 41(5-76) 47(14-78) 
Cerebrovascular event % of patients 7 5 
 Age(SD) 38.6(12) 43.2(14) 
 Median(range) 38(18-80) 43(19-67) 
 
 
22    Current Pharmaceutical Design, 2013, Vol. 19, No. 00 Tuttolomondo et al. 
Table 18. Age at diagnosis 
 Males (n=882) Females(n=718) 
Mean (SD)age(years) 25.7(15) 32.2(18) 
Median age(range)(years) 23(0-81) 32(0-80) 
Distribution(%)   
0 to<10 years 16 9 
10 to <20 years 25 16 
20 to <30 years 19 17 
30 to <40 years 18 17 
40 to <50 years 12 17 
50 7 16 
Unknown  3 7 
 
signs (31%), gastroenterological symptoms (19%), renal signs (un-
specified) (17%), and ophthalmological signs (11%). First symp-
toms in females included neurological pain (41%), gastroen-
terological symptoms (13%), ophthalmological (12%), and skin 
signs (12%). For those patients reporting renal progression, the 
median age at occurrence was 38 years for both sexes, but onset of 
cerebrovascular and cardiovascular events was later in females 
(median 43 and 47 years, respectively) than in males (38 and 41 
years, respectively).  
 These findings demonstrate that in spite of the considerable 
burden of disease in both sexes that begins to manifest in childhood 
or adolescence, the recognition of the underlying diagnosis is de-
layed by 14 years in males and 19 years in females and that AFD is 
often a multiorgan disease. This awareness could offer a possible 
way that can increase detection of common symptoms in all age 
groups, as well as insight into treated and untreated disease course, 
leading to improved recognition and earlier treatment, and possibly 
to improved outcomes for affected individuals. 
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